AdvisorShares Investments LLC Has $1.29 Million Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

AdvisorShares Investments LLC raised its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 113.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 10,460 shares of the specialty pharmaceutical company’s stock after buying an additional 5,560 shares during the quarter. AdvisorShares Investments LLC’s holdings in Jazz Pharmaceuticals were worth $1,288,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. LSV Asset Management raised its stake in shares of Jazz Pharmaceuticals by 1.5% in the fourth quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company’s stock valued at $311,699,000 after purchasing an additional 37,108 shares in the last quarter. Pacer Advisors Inc. raised its stake in shares of Jazz Pharmaceuticals by 5.5% in the 4th quarter. Pacer Advisors Inc. now owns 2,214,480 shares of the specialty pharmaceutical company’s stock valued at $272,713,000 after buying an additional 115,102 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Jazz Pharmaceuticals by 18.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company’s stock valued at $250,619,000 after buying an additional 320,724 shares in the last quarter. Capital World Investors lifted its holdings in shares of Jazz Pharmaceuticals by 5.7% during the 4th quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company’s stock worth $236,860,000 after acquiring an additional 104,195 shares during the period. Finally, JPMorgan Chase & Co. boosted its position in shares of Jazz Pharmaceuticals by 4.8% during the 4th quarter. JPMorgan Chase & Co. now owns 1,587,541 shares of the specialty pharmaceutical company’s stock valued at $195,506,000 after acquiring an additional 72,007 shares in the last quarter. 89.14% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on JAZZ. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $130.00 to $170.00 in a report on Thursday, February 13th. Royal Bank of Canada lowered their price target on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a research report on Wednesday, February 26th. HC Wainwright increased their price objective on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a research note on Monday, March 10th. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the company from $145.00 to $179.00 in a research note on Friday, March 7th. Finally, Piper Sandler reissued an “overweight” rating and set a $176.00 price target (up from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $187.71.

Jazz Pharmaceuticals Stock Up 1.9 %

Jazz Pharmaceuticals stock opened at $112.89 on Tuesday. The company has a 50 day moving average of $124.20 and a 200-day moving average of $122.44. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a twelve month low of $95.49 and a twelve month high of $148.06. The stock has a market capitalization of $6.86 billion, a PE ratio of 15.90, a price-to-earnings-growth ratio of 1.04 and a beta of 0.42.

Insider Transactions at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 3,800 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the sale, the executive vice president now owns 33,318 shares of the company’s stock, valued at approximately $4,826,778.66. The trade was a 10.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Patricia Carr sold 1,140 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $137.81, for a total value of $157,103.40. Following the transaction, the chief accounting officer now directly owns 7,012 shares of the company’s stock, valued at $966,323.72. This trade represents a 13.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 28,736 shares of company stock valued at $4,023,305 over the last three months. Company insiders own 4.20% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.